No Data
No Data
Tonghe Pharmaceutical (300636): The inflection point has reached an impressive Q1 performance; new products bring a new cycle
Incident: The company released its 2023 annual report and 2024 quarterly report. The revenue for 2023 was 722 million yuan, up 0.31% year on year, and net profit to mother was 106 million yuan, up 5.28% year on year, after deducting non-net profit
Tonghe Pharmaceutical (300636) 2023 Report and 2024 Quarterly Report Review: 24Q1 showed significant month-on-month improvement, and new production capacity is about to be put into operation
Note: Recently, the company published its 23 annual report and 24 quarterly report. Revenue of $722 million (+0.31%), net profit attributable to mother of $106 million (+5.28%), net profit of non-return to mother of $98 million
Express News | Tonghe Pharmaceutical: Judging from the performance in the first quarter, sales of new products already account for more than half of revenue and will continue to increase in the future
Pacific released a research report on April 26 stating that Tonghe Pharmaceutical (300636.SZ) was given a purchase rating. The main reasons for the rating include: 1) Q1 performance exceeded expectations and profitability was greatly improved; 2) new prod
Pacific released a research report on April 26 stating that Tonghe Pharmaceutical (300636.SZ) was given a purchase rating. The main reasons for the rating include: 1) Q1 performance exceeded expectations and profitability was greatly improved; 2) new product patents are expiring one after another, and it is expected that the standardized market will begin to expand rapidly; 3) production capacity is about to be launched to ensure medium- to long-term performance growth. (Mainichi Keizai Shimbun)
Tonghe Pharmaceutical (300636) 2023 Annual Report and 2024 Quarterly Report Review: Q1 performance exceeds market expectations, new product regulations are about to expand the market
On the evening of April 24, 2024, the company released its 2023 annual report. In 2023, the company achieved operating income of 722 million yuan (YoY +0.31%) and net profit of 106 million yuan (YoY)
Tonghe Pharmaceutical (300636.SZ) reported first-quarter results, net profit of 43.5628 million yuan, an increase of 31.62% over the previous year
Tonghe Pharmaceutical (300636.SZ) released its report for the first quarter of 2024, with revenue of 206 million yuan, a year-on-year decrease of 6.47%. Net profit attributable to shareholders of listed companies was 43.5628 million yuan, an increase of 31.62% over the previous year. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 404.8876 million yuan, an increase of 23.31% over the previous year. Basic earnings per share were $0.1037.
No Data